The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma
It promises fewer injections for vision loss patients
Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The new centre brings advanced corneal procedures pioneered in India
In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
Subscribe To Our Newsletter & Stay Updated
